TaiGen Biotechnology Co., Ltd.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Taipei United States (2001)

Organization Overview

First Clinical Trial
2006
NCT00434291
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Dongguan HEC Biopharmaceutical R&D Co., Ltd. | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Jubilee Clinical Trial Center, Hammanskraal, South Africa | Mercantile Clinical Trial Center, Korsten, South Africa | TaiGen Biotechnology Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Diabetic Foot (Phase 2)

Fibrosis (Phase 3)

Focal Infection (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Hodgkin Disease (Phase 2)

Infections (Phase 2)

Liver Diseases (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Pneumonia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 12